Veolia Environnement reported a total of 742,496,650 shares forming its share capital as of August 31, 2026. The French utility firm confirmed that while the theoretical number of voting rights matches the total share count, the exercisable portion stands at 732,063,790 due to treasury share holdings.
American drivers are navigating the most expensive Labor Day travel weekend on record, with national gasoline prices climbing to $4.15 per gallon. This sharp increase, fueled by escalating crude oil costs and persistent supply chain disruptions, shatters the previous 2012 holiday record of $3.82 by a significant margin.
After years of litigation stemming from the 2008 collapse of Italian lender Banca Monte dei Paschi di Siena, Deutsche Bank has finalized a confidential settlement with former employee Dario Schiraldi. The agreement resolves claims of career damages following Schiraldi’s initial conviction and subsequent acquittal in the Italian courts.
TotalEnergies SE disclosed its latest capital structure as of August 31, 2026, confirming a total of 2,281,656,714 outstanding shares. The energy giant’s regulatory filing clarifies the distinction between theoretical voting power and the volume of rights currently exercisable by shareholders following the deduction of treasury holdings.
A sudden retreat from a mandatory national recycling policy in France triggered a 6.6% sell-off in Tomra Systems shares on Monday. The decision to abandon the plastic bottle deposit scheme, once championed by President Emmanuel Macron, strips away a major growth catalyst for the Norwegian manufacturer of reverse vending technology.
Jaguar Land Rover plans to eliminate approximately 4,000 positions, representing 9% of its total workforce, as the British manufacturer struggles against mounting U.S. tariffs and a surge of high-tech competition from domestic Chinese automakers that have rapidly eroded the market share of established international brands.
Clinical data for rentosertib, an experimental drug originally developed to treat idiopathic pulmonary fibrosis, suggests the molecule may possess latent anti-aging properties. Published in Nature Biotechnology, the findings mark a shift from repurposing existing generic medicines to using purpose-built, AI-discovered therapies to address the underlying mechanisms of human aging.
TotalEnergies has reached a pivotal juncture for its Papua LNG project, cutting projected capital expenditures to US$14 billion through design optimizations and a strategic shift in leadership. By transferring operatorship to ExxonMobil, the company aims to leverage existing infrastructure synergies to secure the project's long-term viability in Asian energy markets.
Hagihara Industries saw its net profit slip to 1.49 billion yen for the nine months ending July 31, down from 1.56 billion yen during the same period last year. While the company successfully expanded its top-line revenue, increased costs or tax adjustments weighed on the final bottom-line results for shareholders.
Chief Executive Officer Pietro Labriola and a group of senior managers at Telecom Italia have committed their personal equity holdings to the ongoing acquisition effort by Poste Italiane. This move signals internal alignment with the 13 billion euro takeover bid that the company’s board officially endorsed last week.
I'll Inc. closed its fiscal year on July 31 with a net profit of 4.18 billion yen, marking a significant climb from the 3.49 billion yen recorded in 2025. The Japanese firm’s latest financial report highlights steady expansion across its primary revenue streams and operational efficiency gains throughout the twelve-month period.
A$4.75 per share in cash was not enough to sway the board of Ingenia Communities, which on Monday rejected a $1.4 billion takeover bid from private-equity giant Warburg Pincus. Independent directors argued the offer substantially undervalued the Australian retirement village and holiday park operator, dismissing the unsolicited proposal.
A late-stage clinical trial for a heart disease treatment developed by Ionis Pharmaceuticals and Novartis failed to reach its primary endpoint, triggering a sharp sell-off in both companies’ stocks during after-hours trading on Friday as investors reacted to the unexpected setback in their cardiovascular development pipeline.
A 7.5% drop in after-hours trading greeted Corvex shareholders Friday as the company revealed a $26.3 million loss for the first half of the year. Despite the post-market retreat to $13.63, the stock retains a 141% gain for the year, bolstered by a strong performance during the regular session.
Novartis confirmed on Friday that its experimental heart disease drug, pelacarsen, failed to meet the primary endpoint in a critical Phase 3 study. The treatment, originally licensed from Ionis Pharmaceuticals, did not achieve a statistically significant reduction in cardiovascular events, including heart attacks, strokes, and deaths, when measured against a placebo.
Industrial and transportation shares retreated on Tuesday as robust employment data triggered a sharp rise in Treasury yields. The market shift reflects investor anxiety that a resilient labor market may force the Federal Reserve to maintain elevated interest rates longer than anticipated, putting pressure on capital-intensive sectors.
Energy sector shares retreated today as traders recalibrated their portfolios for a potential interest rate hike this September. The shift in market sentiment follows surprisingly robust August employment data, which prompted analysts to reassess the Federal Reserve's likely trajectory for monetary policy in the coming weeks.
Global commodity markets took a sharp downturn this week as investors recalibrated their expectations for interest rate hikes. The retreat in metals and agricultural futures reflects a growing consensus that persistent inflation will force central banks to maintain aggressive monetary policies, despite earlier hopes for a shift toward dovish cooling.
Diesel prices reached record highs this week, triggering a sharp sell-off in consumer-facing stocks. While the surge in fuel costs directly pressures freight and logistics networks, the retail sector is simultaneously navigating a cooling appetite for once-dominant apparel brands as consumer fashion preferences shift toward more eclectic wardrobes.
A sudden retreat from high-risk biotechnology and obesity-drug manufacturers dragged health-care stocks lower today. While the sector has enjoyed a sustained rally fueled by oncology breakthroughs and feverish merger activity, traders are now opting to lock in profits rather than chase further gains in the volatile sub-sector.
American employers added 162,000 workers to payrolls in August, a figure roughly triple economist projections. This unexpected labor market strength immediately cooled investor appetite for stocks, as the data signaled that the Federal Reserve may face renewed pressure to tighten monetary policy to combat persistent inflation risks.
A robust labor market report has triggered a retreat in technology shares, as investors recalibrate their outlook on interest rates. The renewed inflationary pressure, signaled by strong employment data, overshadowed recent sector gains and prompted a broad reassessment of growth valuations across the tech landscape.
Financial stocks retreated on Tuesday as market sentiment soured over the looming prospect of a Federal Reserve interest rate hike in September. The downward pressure rippled across the sector, exacerbated by a sudden regulatory shift that threatened the long-standing dominance of traditional credit-scoring models.
A retreat from risk-heavy sectors sent communications services shares tumbling as investors braced for potential interest rate hikes. The broad sell-off reflects a tightening market climate, where tech-adjacent firms face heightened scrutiny and defensive repositioning from traders looking to insulate portfolios against upcoming volatility in the broader economic landscape.
Rising Treasury yields are keeping a lid on the utility sector, forcing power producers into a defensive posture despite a steady climb in electricity demand. Investors continue to treat these stocks as bond proxies, leaving the industry vulnerable to broader shifts in interest rate expectations and debt market volatility.
Seeking to capitalize on the unique economic landscape of the North Atlantic, blank-check firm New Iceland Arctic Acquisition has filed for a $125 million initial public offering. The company intends to leverage its regional expertise to identify high-growth targets located within Iceland and the broader Arctic circle.
A $41 million price tag marks the end of an era for Cinemas 123, as Reading International prepares to hand over its Manhattan property to 1001 Third Avenue LLC. The transaction, slated to close around October 30, signals a broader shift in the company’s real estate strategy within a softening city market.
The Food and Drug Administration has granted accelerated approval to AstraZeneca’s Etcamah, a new treatment targeting advanced breast cancer. The medication, known generically as camizestrant, is designed for use in combination with a CDK4/6 inhibitor to address specific genetic mutations in patients battling HR-positive, HER2-negative metastatic disease.
Mark Johnson will join Laird Superfood as chief financial officer this October, stepping into a dual role that encompasses the company's principal financial and accounting functions. He joins the executive team following a tenure at Tropicana Brands Group, where he served as vice president of finance for North America.
ADARx Pharmaceuticals has officially initiated its path to the public markets, filing documents with the Securities and Exchange Commission on Friday. The late-stage biotechnology firm, which specializes in siRNA therapeutic development, intends to list its common stock on the Nasdaq Global Market under the ticker symbol ADRX.
